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Abstract
Markov models are often used to evaluate the cost-effectiveness of new healthcare interventions but they are some-
times not flexible enough to allow accurate modeling or investigation of alternative scenarios and policies. A Markov
model previously demonstrated that a one-off invitation to screening for abdominal aortic aneurysm (AAA) for men
aged 65 y in the UK and subsequent follow-up of identified AAAs was likely to be highly cost-effective at thresholds
commonly adopted in the UK (£20,000 to £30,000 per quality adjusted life-year). However, new evidence has
emerged and the decision problem has evolved to include exploration of the circumstances under which AAA screen-
ing may be cost-effective, which the Markov model is not easily able to address. A new model to handle this more
complex decision problem was needed, and the case of AAA screening thus provides an illustration of the relative
merits of Markov models and discrete event simulation (DES) models. An individual-level DES model was built
using the R programming language to reflect possible events and pathways of individuals invited to screening v. those
not invited. The model was validated against key events and cost-effectiveness, as observed in a large, randomized
trial. Different screening protocol scenarios were investigated to demonstrate the flexibility of the DES. The case of
AAA screening highlights the benefits of DES, particularly in the context of screening studies.
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Modeling will almost always constitute an essential com-
ponent of an economic evaluation to inform decision
making, to overcome the limitations of available rando-
mized trial data.1 In screening studies, where much of
the cost is upfront and benefits accrue over a long period
of time, there is a need for modeling approaches that can
contribute to long-term economic evaluations. The
choice of modeling technique is at the discretion of the
analyst and often reflects an implied trade-off between
simplicity and realism in reflecting a disease’s natural
history, treatment, and patient outcomes.2,3 Markov
models have been widely used, as they provide a simple
mechanism to estimate the long-term costs and effects of
healthcare interventions.4 Discrete event simulation
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(DES) is a less common alternative that avoids the use of
states and fixed cycle lengths and instead models events
at the individual level. Some have suggested that DES
should always be preferred, whereas others have high-
lighted particular circumstances where DES should be
favoured.5,6 The case of abdominal aortic aneurysm
(AAA) screening offers an illustration of the relative
merits of these techniques.
An AAA is commonly defined as an aortic diameter
3.0 cm. A long-term Markov model demonstrated that
offering population screening for AAA to men aged 65 y
in the UK was likely to be highly cost-effective.7 This
model was largely populated using data from the 4-y
follow-up of the randomized Multicentre Aneurysm
Screening Study (MASS),8 and adopted the same screen-
ing methods, surveillance intervals (for 3.0 to 5.4 cm
AAAs) and AAA diameter threshold (5.5 cm) for refer-
ral for elective surgical intervention as in MASS. The
MASS trial of 67,800 men aged 65 to 74 showed that an
invitation to a one-off ultrasound scan and surveillance
or referral for elective surgical intervention of identified
AAAs was effective in reducing AAA-related mortality,
initially at the 4-y follow-up,8 and subsequently at
longer-term follow-up.9 The results from the modeling
and the MASS trial formed a large part of the evidence
base supporting the phased implementation from 2009
of the NHS AAA Screening Programme (NAAASP) in
England, with full coverage across the UK by the end of
2013.
Research into the clinical and cost-effectiveness of
AAA screening has evolved since the first Markov mod-
eling was performed, with the emergence of new data
and evidence. Initial observational data from NAAASP
suggested that the current prevalence of AAAs is sub-
stantially lower than that observed in MASS (1.6% v.
4.9%). The Markov model (MM) was updated to reflect
this lower prevalence as well as changes in costs, the
increased use of endovascular surgical techniques, meta-
analyzed data on growth and rupture rates,10,11,11 and
longer-term MASS follow-up.12 The results suggested
screening is still likely to be highly cost-effective, with a
long-term incremental cost-effectiveness ratio of £7,370
(95%CI, £5,467 to £9,443) per quality-adjusted life year
(QALY). Other studies based on populations in
Denmark13 and Sweden,14 with similar AAA prevalence,
support this conclusion.
However, different programs and randomized trials
have adopted diverse surveillance intervals, with little
consensus on optimal intervals.15 More substantial sur-
veillance data from the RESCAN project was incorpo-
rated into an adapted MM to investigate different
surveillance intervals, and the results suggested that
lengthening the time between rescans for men with the
smallest aneurysms could be done at acceptable clinical
risk10 and would be a cost-effective strategy.11 Some of
the protocols around screening have also come under
scrutiny. For example, the definition of an AAA as an
aortic diameter 3.0 cm is somewhat arbitrary: there is
evidence that many individuals with screen-detectable
sub-aneurysmal aortic dilation (2.5 to 2.9 cm) will prog-
ress to AAA within 10 y.16 The implications for screening
remain unclear. There have also been some suggestions
that the surgical threshold itself should be altered.17
In light of these findings, the decision problem no lon-
ger relates only to ‘‘screening’’ v. ‘‘no screening’’ for older
men but has evolved to include the circumstances under
which screening may be cost-effective.18-21 Modeling
allows these questions to be addressed without conduct-
ing costly primary research and could extend to varying
a number of fixed parameters (e.g., surveillance intervals,
the AAA diameter threshold for referral for elective sur-
gery, screening of women, targeted screening based on
patient characteristics). However, MMs can be inflexible.
This inflexibility was demonstrated by the extensive re-
programming needed to build tunnel states in the MM
when the model was adapted to assess different surveil-
lance intervals.11 Such analyses are important for existing
programs aiming to improve their performance or extend
population coverage, as well as for other countries con-
sidering implementation. Therefore, a model better able
to handle this decision problem is required. This paper
describes: 1) the development and validation of a DES
model to estimate the clinical and cost-effectiveness of
AAA screening; and 2) the use of the DES to explore the
cost-effectiveness of screening under various scenarios,
which was not possible with the original MM.
Methods
Development of a Simulation Model
A DES was implemented using the freely available statis-
tical programming language R and based on the original
MM.7 The original MM defined several health states that
related to AAA identification, aortic diameter (\3.0 cm,
3.0 to 4.4 cm, 4.5 to 5.4 cm, 5.5 cm) and associated
events (rupture, surgical consultations, elective and emer-
gency AAA repair, death). A set of transition probabil-
ities determined movements between health states for the
two populations (invited to screening and not invited).
The MM operates at the cohort level: events, mean costs,
and QALYs are calculated from the proportions of the
cohort that inhabit the different health states in each 3-
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mo cycle. In contrast, the DES functions at an individual
level, simulating sequences of events that occur as a con-
tinuous process over time and calculating the associated
mean costs and QALYs. It allows individual patient het-
erogeneity to be characterized and accounts for events as
they occur, removing the need for any assumptions relat-
ing to averaging costs or outcomes across cycles.
An Event Scheduling Approach
Full details of the DES are available in the SWAN proj-
ect National Institute for Health Research Health
Technology Assessment monograph. The DES adopts
an event-scheduling approach by generating a sequence
of events for each individual, using a list of events that
are ‘‘scheduled’’ for the future (future events list; FEL).
The DES has an explicit simulation clock, chooses the
event that has the earliest sampled time, and records it in
the individual’s sequence of events. It then schedules,
reschedules, or cancels other scheduled events as neces-
sary, updating the FEL (for example, if a surveillance
rescan finds that an individual’s aortic diameter is above
the threshold for elective surgery, then a consultation is
scheduled). This process is repeated until death or cen-
soring (dependent on model time horizon). The possible
sequences of events are shown in Figure 1.
Individuals are assigned an aortic diameter, drawn
from a population distribution, and a latent parameter
describing the growth rate of their aorta over time.
Details of the aortic growth model are given in the
Supplementary Material. Non-AAA death and AAA
rupture events are scheduled in the future, and if the indi-
vidual is in the ‘‘invited’’ group, then an invitation is also
scheduled. If the individual is in the ‘‘non-invited’’ group,
then an ‘‘incidental detection’’ event is scheduled. The
time to AAA rupture is dependent on the individual’s ini-
tial aortic diameter and their latent growth rate. In most
instances, the scheduled AAA rupture time will be so far
in the future that there is no chance of the event occur-
ring. The ‘‘incidental detection’’ event is scheduled to
occur only after the time at which an individual’s aortic
diameter reaches the diagnosis threshold (e.g., 3.0 cm).
The DES simulates people in pairs, like identical
twins, one of whom is in the invited group and one in
the non-invited group. The twins have certain character-
istics in common: they have the same times of non-AAA
death and AAA rupture in their FELs, the same initial
aortic diameter and growth rate, and the same values of
certain parameters, such as indicators (binary variables)
for whether they would be contraindicated for surgery
and whether they would survive emergency surgery.
Differences in costs and outcomes result from the differ-
ent events that are scheduled due to involvement or oth-
erwise in the screening programme.
Joint Continuous AAA Growth and Rupture
Model
A major difference between the DES and the MM is that
the DES uses a joint continuous-time model for aortic
growth and rupture11 rather than defining 4 AAA size
states. Additionally, when an individual’s aorta is
scanned, the measurement is generated by calculating the
diameter according to this model and adding measure-
ment error, which is specific to the type of scan used
(i.e., ultrasound or computed tomography [CT]). Further
alterations related to the move from fixed cycles to a
continuous process were made. For example, surgical
waiting time was previously separated into two periods:
the time from discovery to consultation (71 d) and from
consultation to surgery (59 d).22 In the MM, it was
assumed that this total waiting time could be considered
as a 3-mo cycle. The DES would enable these periods to
be easily changed if appropriate.
A Hierarchy of Functions
The R program for the DES is made up of a hierarchy of
functions or routines: 1) a probabilistic sensitivity analy-
sis (PSA), which consists of running the main analysis
multiple times; 2) the main individual patient simulation
analysis, which consists of simulating and analyzing mul-
tiple pairs of individuals; 3) the function to process one
pair; and 4) the function to generate a sequence of events
for an individual. These functions are shown in Figure 2.
The R code developed for this project is available on
request from the authors.
The DES involves a large number of parameters.
These can be classified into several sets: global fixed
parameters, global uncertain parameters, and parameters
that are specific to an individual or a pair of twins (‘‘glo-
bal’’ refers to population parameters and ‘‘uncertain’’
means that a parameter follows a random distribution).
Like the functions, these sets form a hierarchy. For
example, in a PSA, a beta distribution is used to generate
the probability that an individual will die following
emergency surgery, if they have emergency surgery. The
parameters of the beta distribution are global fixed para-
meters, and the probability is a global uncertain para-
meter. In the main analysis, when a pair of twins is
created, the probability is used as the parameter in a
Bernoulli distribution to generate the indicator for the
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twins’ emergency surgery outcomes. The indicator is a
variable specific to the pair of twins.
The hierarchy extends downward by two more levels.
When the DES generates an individual’s sequence of
events, it needs to record the intervention group (i.e.,
invited or not), which can be regarded as an individual-
specific parameter, and when an aorta measurement is
generated, a new and unique value of the measurement
error is created, which can be regarded as an event-
specific parameter. Figure 2 shows how the sets of para-
meters are passed from one function to another. The
definitions of the parameters require judgement and
depend on the nature of the input data. For instance,
the costs of the scans and other events could be defined
as global fixed parameters, if their values are known
with great certainty, or global uncertain parameters if
they are not.
Cost-effectiveness Analysis
The cost-effectiveness analysis consists of simulating a
large number of individuals, calculating their life-years
and costs, and calculating the mean life-years and costs
over all the patients in the groups invited to screening
and not invited. Given that the model outputs are driven
by those individuals who have an AAA, these individuals
were oversampled (and later calculations were adjusted
to account for this), which reduces considerably the
Monte Carlo error when estimating incremental effects
and costs. PSA is conducted to account for uncertainty in
Figure 1 Possible sequences of events in the abdominal aortic aneurysm (AAA) screening discrete event simulation model.
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Figure 2 Abdominal aortic aneurysm (AAA) screening discrete event simulation model: Hierarchy of functions.
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the model parameters; repeated sets of values for the glo-
bal uncertain parameters are generated, and the main
analysis is run for each set of values. The mean incremen-
tal cost and effectiveness (i.e., QALYs), together with the
incremental cost-effectiveness ratio (ICER) and incremen-
tal net monetary benefit (INMB), are calculated for each
set, and the distribution of values is used to estimate the
probability that the screening program is cost-effective.
Programming Practice
The DES is a moderately complicated computer program,
and it was therefore necessary to follow basic principles of
good programming to ensure that it would run correctly
and be maintainable and usable in the future. For exam-
ple, each function has a clearly defined single purpose that
can easily be understood from its name, and priority was
given to making the source-code simple, clear, and read-
able (by other people) rather than computationally fast.
The DES was written using a mostly ‘‘functional’’ pro-
gramming style: the basic building-blocks are functions,
and functions do not modify things outside themselves but
simply perform actions and then either display output or
return relevant quantities (e.g., parameters, event-times).
R is convenient for statistical and scientific programming,
and it allows loops (or iterative processes) to be written to
run in parallel (which is not the case with all programming
languages). The DES is eminently suited to parallelization,
which speeds it up considerably.
Model Validation
The original MM was validated against the MASS trial
4-y follow-up to check the appropriateness of model out-
puts. The validation involved comparing the numbers of
key events (e.g., AAA ruptures, number of elective oper-
ations) and mean costs and life-years, as observed in the
trial, with model outputs based on a simulated popula-
tion of the same size. The MM was able to replicate the
observed data reasonably.7,23 For the DES, a similar pro-
cess was carried out, again using the 4-y MASS follow-
up data. Costs and life-years were discounted at 6% and
1.5% per y, respectively, to be consistent with the origi-
nal rates used in the 4-y follow-up analysis.
Input parameters for the DES were derived from the
MASS 4-y follow-up, where possible, including non-
AAA death rates, to enable validation. Other adapta-
tions were made to improve the DES model fit to the
observed MASS outputs. The parameters for the aorta
growth model were chosen such that, at baseline, there
were the same proportions of individuals with aortic size
\3.0 cm, 3.0 to 4.4 cm, 4.5 to 5.4 cm and 5.5 cm as in
MASS. Growth rates were based directly on those
observed in the screen-detected MASS population, with
growth rates for those 2.0 to 2.9 cm extrapolated from a
fitted mixed model, and growth rates set to zero for
those \2.0 cm at baseline (see Supplementary Material
for more details). All aorta measurements that were per-
formed by CT scan (at consultation only) were, on aver-
age, 0.24 cm larger than an ultrasound scan, to account
for CT scanning measuring outer-to-outer rather than
inner-to-inner diameters.11 Individuals were censored at
uniformly random times between 3 and 5.25 y, because
the ‘‘4-y’’ follow-up of the MASS data had censoring
times similar to this uniform distribution. Full details of
the input parameters and characterization of uncertainty
is detailed in Supplementary Table 1.
New Model Scenarios
After validation against the MASS trial 4-y follow-up,
parameter values in the DES were updated to reflect more
contemporaneous estimates, the full details of which are
provided in Supplementary Table 2. National mortality sta-
tistics24 were used for non-AAA death rates. The NAAASP
baseline aortic diameter distribution was used in the aorta
growth and rupture model, with growth and rupture rates
based on RESCAN data.25 As before, growth rates \3.0
cm were extrapolated from a model or were set to zero.
Costs, attendance rate, and other parameters were updated
as described by Glover and others,12 with QALYs esti-
mated by applying population norm utility weights to life-
years accrued. The model structure was further altered to
allow for endovascular aneurysm repair (EVAR) as well as
open repair, with a proportion of surgery by EVAR, which
incurred a different cost and post-operative mortality rate
compared to open surgery.11 The base case was run over a
30-y time horizon for 65-y-old men invited or not invited to
screening, for 10 million pairs of individuals. PSA, based on
1,000 runs with 500,000 pairs of individuals, was used to
characterize uncertainty in input parameters. Costs and
QALYs were discounted at 3.5% per y.
Two modeling scenarios were explored, showing the
flexibility of the DES to estimate the cost-effectiveness of
screening under various protocols. The first built on an
analysis previously performed using the MM, to identify
more cost-effective surveillance intervals for men in the
screening program.11 The second allowed the inclusion
of surveillance for men with sub-aneurysmal aortic dia-
meters (2.5 to 2.9 cm at first screen). Each of these differ-
ent scenarios was compared to the existing program in
terms of costs and QALYs.
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Scenario 1: Different Surveillance Intervals. Analysis
performed using the MM suggested that lengthening sur-
veillance intervals for the smallest identified AAAs
would be cost-effective according to thresholds com-
monly adopted in the UK (£20,000 to £30,000 per
QALY).11 However, the different surveillance strategies
considered were limited to varying the time between
monitoring for two AAA size groups (3.0 to 4.4 cm, and
4.5 to 5.4 cm). Unlike the MM, the DES can be easily
adapted to use any number of plausible AAA size cut-
offs, or to consider differing surveillance intervals. Here,
the current NAAASP surveillance strategy of 1-year (3.0
to 4.4 cm AAAs) and 3-month (4.5 to 5.4 cm AAAs)
intervals is compared to a strategy of 2-year (3.0 to 3.9
cm AAAs), 1-year (4.0 to 4.4 cm AAAs), and 3-month
(4.5 to 5.4 cm AAAs) intervals.
Scenario 2: Inclusion of Sub-aneurysmal (2.5 to 2.9 cm)
Aortas. The threshold definition of an AAA used in the
DES was lowered from 3.0 cm to 2.5 cm. Individuals
identified with an aortic diameter of 2.5 to 2.9 cm had
surveillance scans scheduled at intervals of 5 years, with
the intervals currently adopted by NAAASP maintained
for AAAs between 3.0 cm and 5.4 cm.
Results
DES Model Validation
The DES validated reasonably against the MASS 4-y
data. The DES broadly agreed with both the observed
MASS 4-y follow-up and the original MM in terms of
differences in life-years and costs (Table 1). However,
like the MM, the 4-y ICER for the DES was higher than
in the MASS data. Table 2 shows the total numbers of
events as observed in MASS and estimated by the origi-
nal MM and the DES. For most events, the numbers of
events were similar, as were the ratios of events in the
DES to events in MASS show. The numbers of non-
AAA deaths matched very closely, primarily because the
MM and DES used non-AAA death rates from MASS
and most individuals do not experience AAA rupture.
As examples of cumulative events over time, Figure 3
shows the numbers of emergency operations in the non-
invited group and AAA deaths in the invited group esti-
mated by the DES, compared to the observed numbers
in the MASS 4-y follow-up.
New Model Scenarios
The updated model after validation, using contempora-
neous data sources, estimated a 30-y ICER of £6,352
(95%CI, £5,059 to £8,808) per QALY (Table 3). This
compares to a 30-y ICER of £7,370 produced by the
MM.12 The 1,000 iterations on the cost-effectiveness
plane and cost-effectiveness acceptability curve shown in
Figure 4 demonstrate that a one-off invitation to AAA
screening and subsequent follow-up of identified AAAs
is highly likely to be cost-effective, with no iterations
outside the cost-effective region.
The estimated INMBs for both new scenarios were
positive when compared with the existing screening pro-
gram at a willingness-to-pay threshold of £20,000 per
QALY (Table 4). The longer surveillance interval for the
Table 1 Life-years and Costs According to the 4-y MASS Follow-up, Markov Model (Kim and others7) and the DESa
MASS Observed Markov Model DES Model
Non-invited group
Life-years 3.816 3.905 3.753
Cost £35.03 £32.74 £39.11
Invited group
Life-years 3.819 3.907 3.754
Cost £98.42 £98.32 £101.97
Difference
Life-years 0.0022 0.0017 0.0015
Cost £63.39 £65.58 £62.86
ICER £28,400 £37,700 £42,137
(95% CI) (£15,000, £146,000) (£19,700, £147,000) (£19,935, £3,277,596)b
DES, discrete event simulation; ICER, incremental cost-effectiveness ratio; MASS, Multicentre Aneurysm Screening Study.
aLife-years discounted at 1.5% per y and costs at 6% per y.
bReported as uncertainty interval produced by 1,000 probabilistic sensitivity analysis (PSA) iterations (after assigning ICERs with negative
incremental effects and positive costs to be infinite). Mean estimates from 1,000 PSA iterations for the difference in life-years, costs, and the
ICER were 0.0015, £62.91 and £46,032, respectively.
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smallest AAAs (scenario 1) resulted in a small cost sav-
ing, as those with 3.0 to 3.9cm AAAs are screened less
often than in the existing program. The longer surveil-
lance interval was also associated with almost no change
in QALYs. Extending the surveillance program to those
with 2.5 to 2.9 cm aortic diameters (scenario 2) was asso-
ciated with additional benefits but greater costs.
However, the model suggests that rescanning these indi-
viduals at 5-y intervals could be cost-effective, with an
INMB of £10 per individual invited to screening. The
estimate of the INMB for scenario 1 was positive; how-
ever, the CI from the PSA included zero; the probability
of it being cost-effective compared with the current strat-
egy was 0.68. The INMB for scenario 2, with a CI that
excludes zero, suggests that a surveillance for those with
an aortic diameter between 2.5 and 2.9 cm is a cost-
effective strategy as compared with the current strategy.
Discussion
In assessing screening programs, modeling techniques
are particularly relevant given that most of the costs are
upfront, but benefits continue to accrue over time. The
validated MM built by Kim and others7 demonstrated
that AAA screening for men aged 65 y in the UK was
likely to be cost-effective, but the model was inflexible
when trying to address questions around configuration
and optimization of screening. The creation of the DES
has overcome these problems and the case of AAA screen-
ing highlights situations where DES may provide the most
appropriate method to perform an economic evaluation,
particularly when surveillance or rescreening is based on
patient characteristics or risk markers (in this instance,
AAA size). However, it cannot be asserted that the deci-
sion around the conceptual model should have been differ-
ent at the onset of the research. The evolution of the
decision problem has necessitated the re-conceptualization.
Indeed, the MM served a valuable and timely purpose in
showing the long-term cost-effectiveness of a one-off invi-
tation to screening in the UK for men aged 65 y.
The DES built was based on the original MM, which
itself was largely based on the MASS trial. This allowed
the validation of the DES against observed MASS follow-
up events and cost-effectiveness results. Overall, the DES
validation process was similar to that for the MM, and no
major changes were necessary to produce a comparison of
key outputs. Given that some of the parameters in the
model were not based on data directly observed in MASS
(e.g., incidental detection rate), further calibration to fit
MASS-observed data could have been undertaken to bet-
ter replicate the number of events or the cost-effectiveness
results based on trial data. This type of calibration was per-
formed to produce a better fit using the MM.24 However,
when trying to validate a model against data from a study
Table 2 Key Events Observed in the MASS 4-y Follow-up, and as Estimated by the Markov Model (Kim and others7) and the
DES
MASS Observed Markov Modela DES Modela DES Model (% of MASS)
No invitation group
Elective operation 100 83 98 98
Emergency operation 62 62 68 110
Rupture 138 141 154 112
Contraindicated for elective surgery NA 14 16 NA
AAA death 113 109 120 106
Non-AAA death 3,750 3,724 3,696 99
Invited group
Elective operation
Resulting from screen detection 295 282 330 112
Resulting from incidental detection 31 25 27 86
Emergency operation 28 34 30 106
Rupture 66 78 67 102
Contraindicated for elective surgery
Resulting from screen detection 41 46 54 131
Resulting for incidental detection NA 5 5 NA
AAA death 65 69 63 98
Non-AAA death 3,694 3,724 3,700 100
Loss to recall follow-up 290 289 278 96
AAA, abdominal aortic aneurysm; DES, discrete event simulation; MASS, Multicentre Aneurysm Screening Study; NA, not available.
aEstimated for a sample size of 33,961 participants in the control group and 33,839 in the invited group, as in MASS.
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in this way, there is a risk of creating a cyclical process. If
too much information from the study is used, then the
model output might match the data very well but the
model may not predict well over a longer time horizon,
rather like the issue of overfitting in statistical modeling.
The differences between the DES and MM may be partly
explained by the approach developed to handle aortic
growth of those AAA\3.0 cm at first screen. The perfor-
mance of the DES in the validation gives some confidence
in using the model to extrapolate over a longer term.12,23
The general advantages of DES in health economic
modeling have been extolled previously.2,6,26–28 They
offer a decision modeler greater flexibility to adequately
reflect clinical pathways, characterize baseline patient
heterogeneity, allow event rates that change over time or
depend on patient characteristics, and avoid the con-
straints of state transitions and fixed cycles imposed by
the MM. In the case of AAA screening, there are 3 par-
ticular characteristics that mean that a DES is superior:
firstly being able to define the size of a AAA as a contin-
uous variable, which also allows measurement error in
the ultrasound observations; secondly, allowing hetero-
geneity in the AAA growth rates between different indi-
viduals, with uncertainty easily characterised, something
Figure 3 Cumulative numbers of events in the 4-y MASS data and the DES for: (a) emergency operations in the non-invited
group and (b) AAA deaths in the invited group. AAA, abdominal aortic aneurysm; DES, discrete event simulation; MASS,
Multicentre Aneurysm Screening Study.
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that is difficult to recreate in an aggregate discrete-state
MM, even by varying the transition probabilities over
time; and thirdly the ease with which time-varying sur-
veillance intervals and other changes to the screening
programme can be defined and evaluated. There are gen-
erally perceived trade-offs between the simplicity of an
MM and the complexity of a DES, particularly related
to model build time, potential data requirements, and
model run times; the latter will always be a consider-
ation. However, the advantages of DES models start to
outweigh other factors as the complexity of the decision
problem and modeled pathway increases, especially if
structural modifications and further data analysis are
necessary to deal with different scenarios.
The results of the scenarios presented here would be
difficult to replicate in an MM, constrained by the state
Figure 4 Long-term (30-y) cost-effectiveness of one-off invitation to AAA screening: (a) 1,000 probabilistic sensitivity analysis
iterations (current NAAASP program), (b) cost-effectiveness acceptability curve. AAA, abdominal aortic aneurysm; NAAASP,
National Health Service AAA screening programme .
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transition approach. The problem of modeling different
surveillance intervals was encountered in previous work
on AAA screening and required the re-programming of 6
different incarnations of the MM,11 each containing a
different number of 3-mo tunnel states. For each surveil-
lance interval that was different from the original screen-
ing strategy, tunnel states that allowed unobserved aortic
growth and a related rupture rate in each cycle were nec-
essary. Members of the cohort in these unobserved tun-
nel states were then able to move back into observed
states at each rescan. It would have been desirable to
explore more combinations of screening intervals and
associated AAA size cut-offs. However, the structural
changes that are a necessity in an MM would have made
this a time-consuming process, thus limiting the number
of analyses that could be considered. Conversely, the
DES can easily assess any combination of surveillance
intervals. To change the interval for patients with a 3.0 to
3.9 cm AAA from one to two years is trivial, because the
DES is programmed to allow the input of any chosen
partition of the aortic size range with an associated
screening interval for each part. This is only possible
because an individual’s AAA size is measured on a con-
tinuous scale. The problems of state transition are further
demonstrated when trying to assess the cost-effectiveness
of including sub-aneurysmal AAAs in a screening pro-
gram. In the MM, a new AAA state (2.5 to 2.9 cm with
5-y surveillance intervals) would need to be incorporated,
with extensive reprogramming. In the DES, all that is
necessary is to insert ‘‘2.5’’ in the list of surveillance
thresholds and ‘‘5’’ in the list of intervals. In addition, the
DES parameters can also be easily made to depend on
individual-level covariates (e.g., age-dependent mortality
rates after surgery).
The DES can be used to assess the cost-effectiveness of
other policy-relevant protocol changes, including the surgi-
cal threshold, the age at first screen, and recalling all those
screened normal at first screen after a period of time. The
model has been parametrized as part of the SWAN29 study
Table 3 Discrete Event Simulation: Long Term (30-y) Cost-
effectiveness of One-off Invitation to AAA Screening for 65-y-
old Mena
DES Model
No invitation group
Life-years 12.601
QALYs 9.681
Cost £164
Invited group
Life-years 12.611
QALYs 9.689
Cost £213
Difference
Life-years 0.01031
QALYs 0.00781
Cost £50
ICER (QALYs) £6,352
(95%CI)b (£5,059 to £8,808)
DES, discrete event simulation; ICER, incremental cost-effectiveness
ratio; QALY, quality-adjusted life year.
aLife-years, QALYs, and costs discounted at 3.5% per y.
bReported as uncertainty interval produced by 1,000 probabilistic
sensitivity analysis iterations. Mean estimates from 1,000 PSA
iterations for the difference in life-years, QALYs, costs, and the ICER
were 0.01050, 0.00796, £50 and £6,388, respectively.
Table 4 Long-term (30-y) Cost-effectiveness. Scenario 1: Surveillance Intervals of 2 Y (3.0–3.9 cm AAAs), 1 Y (4.0–4.4 cm
AAAs) and 3 Mo (4.5–5.4 cm AAAs). Scenario 2: Inclusion of Sub-aneurysmal (2.5–2.9 cm) AAAs in Screening Programmea
Current Strategy Scenario 1 Scenario 2
Mean incremental QALYs 0.00781 0.00781 0.00860
Mean incremental cost £49.61 £48.54 £55.17
Compared to current strategy:
Mean incremental QALYs NA 0.00000 0.00080
Mean incremental cost NA -£1.07 £5.56
ICER (QALYs)
(95%CI)b
NA Dominant £7,002
(4,615 to 12,233)
INMBc
(95%CI)b
NA £0.99
(-2.03 to 3.35)
£10.33
(2.99 to 21.52)
ICER, incremental cost-effectiveness ratio; INMB, incremental net monetary benefit; QALY, quality-adjusted life year.
aLife-years, QALYs and costs discounted at 3.5% per y.
bAt a willingness-to-pay of £20,000 per QALY.
cReported as uncertainty interval produced by 1000 probabilistic sensitivity analysis iterations Mean estimates from 1000 PSA iterations for the
difference in QALYs, costs, and the ICER for scenario 1 were 0.00000, £21.08, and NA; and for scenario 2 were 0.00080, £5.58 and £7,233,
respectively.
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and used to assess the likelihood of screening (with various
protocols) women being cost-effective.
The restructuring of the model as a DES was, as might
be expected, a relatively complex undertaking. Nevertheless,
coding in a language such as R enables greater clarity and
transparency compared to software designed for simulation
modeling. However, the computational requirements of the
DES were extensive, given the number of individuals needed
to reduce sampling variation to an acceptable level and
characterizing uncertainty through PSA. Run time was in
the region of 24 h to run the model with 500,000 patients
and 1,000 PSA iterations, even with parallelization and the
use of a high-powered computer.
Acknowledgments
SWAN collaborative group: Simon G. Thompson (Chief
Investigator), Michael J. Sweeting, Edmund Jones, Katya L.
Masconi (University of Cambridge); Janet T. Powell, Pinar Ulug
(Imperial College London); Matthew J. Bown (University of
Leicester); Matthew J. Glover (Brunel University London). The
authors thank colleagues at Brunel University London and in par-
ticular Professor Doug Coyle and Professor Martin Buxton for
comments on versions of this manuscript. Any remaining deficien-
cies or inaccuracies are solely the responsibility of the authors.
Supplementary Material
Supplementary material for this article is available on the
Medical Decision Making Web site at http://journals.sagepub
.com/home/mdm.
ORCID iD
Matthew J. Glover http://orcid.org/0000-0001-9454-2668
References
1. Buxton MJ, Drummond MF, Van Hout BA, et al. Model-
ling in economic evaluation: An unavoidable fact of life.
Health Econ. 1997;6:217–27.
2. Brennan A, Chick SE, Davies R. A taxonomy of model
structures for economic evaluation of health technologies.
Health Econ. 2006;15:1295–310.
3. Halpern MT, Luce BR, Brown RE, Geneste B. Health and
economic outcomes modeling practices: A suggested
framework. Value Health. 1998;1:131–47.
4. Briggs A, Sculpher M. An introduction to Markov
modelling for economic evaluation. Pharmacoeconomics.
1998;13:397–409.
5. Karnon J, Haji Ali, Afzali H. When to use discrete event
simulation (DES) for the economic evaluation of health
technologies? A review and critique of the costs and bene-
fits of DES. Pharmacoeconomics. 2014;32:547–58.
6. Caro JJ, Moller J, Getsios D. Discrete event simulation:
The preferred technique for health economic evaluations?
Value Health. 2010;13:1056–60.
7. Kim LG, Thompson SG, Briggs AH, Buxton MJ, Camp-
bell HE. How cost-effective is screening for abdominal
aortic aneurysms? J Med Screen. 2007;14:46–52.
8. Ashton HA, Buxton MJ, Day NE, et al. The multicentre
aneurysm screening study (MASS) into the effect of
abdominal aortic aneurysm screening on mortality in men:
A randomised controlled trial. Lancet. 2002;360:1531–9.
9. Thompson SG, Ashton HA, Gao L, Buxton MJ, Scott
RA, Multicentre Aneurysm Screening Study (MASS)
Group. Final follow-up of the multicentre aneurysm
screening study (MASS) randomized trial of abdominal
aortic aneurysm screening. Br J Surg. 2012;99:1649–56.
10. RESCAN Collaborators, Bown MJ, Sweeting MJ, Brown
LC, Powell JT, Thompson SG. Surveillance intervals for
small abdominal aortic aneurysms: A meta-analysis.
JAMA. 2013;309:806–13.
11. Thompson SG, Brown LC, Sweeting MJ, et al. Systematic
review and meta-analysis of the growth and rupture rates
of small abdominal aortic aneurysms: Implications for sur-
veillance intervals and their cost-effectiveness. Health Tech-
nol Assess. 2013;17:1–118.
12. Glover MJ, Kim LG, Sweeting MJ, Thompson SG, Bux-
ton MJ. Cost-effectiveness of the national health service
abdominal aortic aneurysm screening programme in Eng-
land. Br J Surg. 2014;101:976–82.
13. Lindholt JS, Juul S, Fasting H, Henneberg EW. Prelimi-
nary ten year results from a randomised single centre mass
screening trial for abdominal aortic aneurysm. Eur J Vasc
Endovasc Surg. 2006;32:608–14.
14. Svensjo S, Bjorck M, Wanhainen A. Current prevalence of
abdominal aortic aneurysm in 70-year-old women. Br J
Surg. 2013;100:367–72.
15. Stather PW, Dattani N, Bown MJ, Earnshaw JJ, Lees TA.
International variations in AAA screening. Eur J Vasc
Endovasc Surg. 2013;45:231–4.
16. Wild JB, Stather PW, Biancari F, et al. A multicentre
observational study of the outcomes of screening detected
sub-aneurysmal aortic dilatation. Eur J Vasc Endovasc
Surg. 2013;45:128–34.
17. Paraskevas KI, Mikhailidis DP, Andrikopoulos V, Bessias
N, Bell SP. Should the size threshold for elective abdominal
aortic aneurysm repair be lowered in the endovascular era?
Yes. Angiology. 2010;61(7):617–9.
18. Powell JT, Thompson SG. Should the frequency of surveil-
lance for small abdominal aortic aneurysms be reduced?
Eur J Vasc Endovasc Surg. 2013;46:171–2.
19. Earnshaw JJ. Should the frequency of surveillance of a
small abdominal aortic aneurysm be reduced? Eur J Vasc
Endovasc Surg. 2013;46:174.
20. The International AAA Screening Group, Bjorck M, Bown
MJ, et al. International update on screening for abdominal
aortic aneurysms: Issues and opportunities. Eur J Vasc
Endovasc Surg. 2015;49:113–5.
21. Davis M, Harris M, Earnshaw JJ. Implementation of
the national health service abdominal aortic aneurysm
450 Medical Decision Making 38(4)
screening program in england. J Vasc Surg. 2013;57(5):
1440-1445.
22. Kim LG. A markov model for long-term cost-effectiveness
modelling of screening for abdominal aortic aneurysms:
Version 2. http://www.mrc-bsu.cam.ac.uk/wp-content/
uploads/A_Markov_model_for_MASS.pdf. Updated 2006.
Accessed 9th July, 2016.
23. Kim LG, Thompson SG. Uncertainty and validation of
health economic decision models. Health Econ. 2010;19(1):
43-55.
24. Office for National Statistics. Interim life tables, england
and wales, 2009-2011. Available from URL: http://
webarchive.nationalarchives.gov.uk/20160105160709/http://
www.ons.gov.uk/ons/publications/re-reference-tables.html?
edition=tcm%3A77-274529. Accessed 18 May 2016.
25. Sweeting MJ, Thompson SG, Brown LC, Powell JT,
RESCAN collaborators. Meta-analysis of individual
patient data to examine factors affecting growth and rup-
ture of small abdominal aortic aneurysms. Br J Surg.
2012;99:655–65.
26. Karnon J. Alternative decision modelling techniques for
the evaluation of health care technologies: Markov pro-
cesses versus discrete event simulation. Health Econ.
2003;12:837–48.
27. Barton P, Bryan S, Robinson S. Modelling in the economic
evaluation of health care: Selecting the appropriate
approach. J Health Serv Res Policy. 2004;9:110–8.
28. Karnon J, Stahl J, Brennan A, et al. Modeling using dis-
crete event simulation: A report of the ISPOR-SMDM
modeling good research practices task force-4. Value
Health. 2012;15:821–7.
29. Screening women for abdominal aortic aneurysms
(SWAN). https://www.journalslibrary.nihr.ac.uk/program
mes/hta/1417901/#/ Accessed December 10 2016.
Glover*, Jones* et al. 451
